AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.032

+0.0026.67%

Volume:16.08M

Turnover:503.52K

Market Cap:74.69M

PE:-0.85

High:0.033

Open:0.030

Low:0.030

Close:0.030

Loading ...

Overview Company News Filings

10 ways to fix Australia’s broken retirement income system

Morning Star AU

BRIEF-Radiopharm Theranostics Logs HY Loss From Ordinary Activities A$18.7 Mln

Radiopharm Theranostics - Hy Loss From Ordinary Activities a$18.7 Million

THOMSON REUTERS

Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock

Simply Wall St.

Do you really need $1 million to retire?

BRIEF-New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

New Clinical Trial Data Highlights Rad 101 (18F-Pivalate) Successfully Detects Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Says its Proprietary Radiotracer Detected Brain Metastases in New Clinical Study; Shares Down 4%

MT Newswires Live

Radiopharm Theranostics Ltd: Previous Guidance of Cash Runway to Mid-2026 Remains

THOMSON REUTERS

Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$125k

Simply Wall St.

BRIEF-Lantheus Increases To 12.16% Shareholding In Radiopharm With US$5M (A$8M) Placement

Lantheus Increases to 12.16% Shareholding in Radiopharm With US$5M (a$8M) Placement

THOMSON REUTERS

Radiopharm Theranostics Ltd - Placement at a$0.060 per Share, 150% Premium to Last Closing Price

THOMSON REUTERS

Radiopharm Theranostics Raises $5 Million Via Private Placement to Lantheus, Shares Surge 58%

MT Newswires Live

2 ASX small-cap shares rocketing 35% to 54% today

$8M deal sees Private Lantheus pick up 12.16% of Radiopharm Theranostics

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.032,"timestamp":1741583520000,"preClose":0.03,"halted":0,"volume":16084721,"delay":0,"changeRate":0.066667,"change":0.002,"floatShares":1544866590,"shares":2333980142,"eps":-0.037714,"lyrEps":-0.124072,"pbRate":1.4,"amount":503521,"amplitude":0.1,"volumeRatio":0.829646,"dividePrice":0,"prevYearClose":0.024,"fiveDayClose":0.026,"twentyDayClose":0.025},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":1544866590,"roa":"-28.87%","roe":"-112.21%","lyrEps":-0.124072,"volumeRatio":0.829646,"shares":2333980142,"dividePrice":0,"high":0.033,"amplitude":0.1,"preClose":0.03,"low":0.03,"week52Low":0.021,"pbRate":"1.40","psRate":"172.97","week52High":0.067,"institutionHeld":0,"latestPrice":0.032,"committee":0.037075,"eps":-0.037714,"divideRate":0,"volume":16084721,"delay":0,"ttmEps":-0.037714,"open":0.03,"prevYearClose":0.024,"prevWeekClose":0.03,"prevMonthClose":0.026,"prevQuarterClose":0.024,"fiveDayClose":0.026,"twentyDayClose":0.025,"sixtyDayClose":0.033},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517705849","title":"10 ways to fix Australia’s broken retirement income system","url":"https://stock-news.laohu8.com/highlight/detail?id=2517705849","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517705849?lang=en_us&edition=fundamental","pubTime":"2025-03-05 00:00","pubTimestamp":1741104000,"startTime":"0","endTime":"0","summary":"This article was provided by a third-party and the opinions expressed here are the author’s. Morningstar values diversity of thought and publishes a broad range of viewpoints.Iheard about the concept of VUCA mentioned on radio the other day. It was used in the context of geo-political instability, but as my passion is helping ordinary Australians understand the almost impenetrable rules of retirement income, VUCA struck a chord.What is it?Here’s what they had to say about what’s needed to improve Australia’s’ retirement income system.David Bell, Executive Director, The Conexus InstituteQuick win:Super funds need to engage with their members more in the lead-up to retirement, introducing them to the decisions they will face and some information materials that they can engage with. Helping future retirees prepare for big, possibly complex, and, in many cases, confronting decisions can only be beneficial. Some funds do this really well as part of what they call their member journey mappin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/insights/retirement/261673/10-ways-to-fix-australias-broken-retirement-income-system","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["RAD","BK7087","ABP","XAO.AU","XJO.AU","XKO.AU","RAD.AU","BK4128","BK4139","BK7067","ABP.AU","BK7154"],"gpt_icon":0},{"id":"2514397956","title":"BRIEF-Radiopharm Theranostics Logs HY Loss From Ordinary Activities A$18.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514397956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514397956?lang=en_us&edition=fundamental","pubTime":"2025-02-28 14:31","pubTimestamp":1740724309,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Logs HY Loss From Ordinary Activities A$18.7 MlnFeb 28 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:HY LOSS FROM ORDINARY ACTIVITIES A$18.7 MILLIONFurther company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2514392538","title":"Radiopharm Theranostics - Hy Loss From Ordinary Activities a$18.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514392538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514392538?lang=en_us&edition=fundamental","pubTime":"2025-02-28 14:11","pubTimestamp":1740723099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2514359832","title":"Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2514359832","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514359832?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:44","pubTimestamp":1740692675,"startTime":"0","endTime":"0","summary":"When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Radiopharm Theranostics Limited's  instance, it's good news for shareholders.While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.The Last 12 Months Of Insider Transactions At Radiopharm Theranostics. The MD, CEO & Director Riccardo Canevari made the biggest insider purchase in the last 12 months. That single transaction was for AU$241k worth of shares at a price of AU$0.031 each. So it's clear an insider wanted to buy, even at a higher price than the current share price . It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-signs-multiple-insiders-buy-214435316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RADX","BK4139","RAD.AU"],"gpt_icon":0},{"id":"2512196365","title":"Do you really need $1 million to retire?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512196365","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512196365?lang=en_us&edition=fundamental","pubTime":"2025-02-19 04:00","pubTimestamp":1739908831,"startTime":"0","endTime":"0","summary":"For decades now, most Australians have had in mind that $1 million is the dream goal to have saved for a comfortable retirement. There’s plenty of articles to say that this figure is a myth, but the truth is a bit more complicated that simply calling out that figure.There’s also the other factor that $1 million quite simply doesn’t buy what it did decades ago when the myth first arose – should the new figure be $2 million based on inflation and today’s cost of living?Then there’s looking at the Association of Superannuation Funds of Australia’s  Retirement Standard which offer up the figure of $595,000 in savings at age 67 for a single person and $690,000 for a couple.It’s hardly a surprise many Australians are confused about retirement. To clear things up, I spoke to Charlie Viola, Executive Chair, Adviser, Founding Partner for Viola Private Wealth and Matt Fenning, CEO for Esencia Wealth for the answers. As a starting point though, you probably want to throw any standardised figures ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/do-you-really-need-1-million-to-retire","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/do-you-really-need-1-million-to-retire","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["RAD.AU","BK7067","BK4128","RAD"],"gpt_icon":0},{"id":"2510854490","title":"BRIEF-New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854490","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854490?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:12","pubTimestamp":1739193123,"startTime":"0","endTime":"0","summary":"BRIEF-New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain MetastasesFeb 10 (Reuters) - Radiopharm Theranostics RAD.AX:NEW CLINICAL TRIAL DATA HIGHLIGHTS RAD 101 (18F-P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUASD6DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2510548808","title":"New Clinical Trial Data Highlights Rad 101 (18F-Pivalate) Successfully Detects Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2510548808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510548808?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUASD6DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2510500577","title":"Radiopharm Theranostics Says its Proprietary Radiotracer Detected Brain Metastases in New Clinical Study; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510500577","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510500577?lang=en_us&edition=fundamental","pubTime":"2025-02-10 11:20","pubTimestamp":1739157643,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.The firm's shares fell 4% in recent trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2507628673","title":"Radiopharm Theranostics Ltd: Previous Guidance of Cash Runway to Mid-2026 Remains","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628673?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:10","pubTimestamp":1738242611,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ1JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2503336549","title":"Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$125k","url":"https://stock-news.laohu8.com/highlight/detail?id=2503336549","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503336549?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:38","pubTimestamp":1736984312,"startTime":"0","endTime":"0","summary":"Insiders who bought AU$651.2k worth of Radiopharm Theranostics Limited ( ASX:RAD ) stock in the last year have seen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/despite-recent-gains-radiopharm-theranostics-insiders-are-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4128","BK7067","RAD.AU","RAD"],"gpt_icon":0},{"id":"2502637708","title":"BRIEF-Lantheus Increases To 12.16% Shareholding In Radiopharm With US$5M (A$8M) Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502637708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502637708?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:17","pubTimestamp":1736515046,"startTime":"0","endTime":"0","summary":"BRIEF-Lantheus Increases To 12.16% Shareholding In Radiopharm With US$5M (A$8M) PlacementJan 10 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:LANTHEUS INCREASES TO 12.16% SHAREHOLDING IN RADIOPHARM W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUACDRDDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2502868438","title":"Lantheus Increases to 12.16% Shareholding in Radiopharm With US$5M (a$8M) Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868438?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUACDRDDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2502864863","title":"Radiopharm Theranostics Ltd - Placement at a$0.060 per Share, 150% Premium to Last Closing Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2502864863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502864863?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUACDRDDJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2502900599","title":"Radiopharm Theranostics Raises $5 Million Via Private Placement to Lantheus, Shares Surge 58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502900599","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502900599?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:15","pubTimestamp":1736475353,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) raise $5 million via the execution of a subscription agreement for a private placement of 133 million ordinary shares to Lantheus Holdings, according to a Friday Aust","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4198","BK4585","BK7067","LNTH","BK4588","RAD.AU"],"gpt_icon":0},{"id":"2502005135","title":"2 ASX small-cap shares rocketing 35% to 54% today","url":"https://stock-news.laohu8.com/highlight/detail?id=2502005135","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502005135?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:08","pubTimestamp":1736471280,"startTime":"0","endTime":"0","summary":"The first full trading week of 2025 is ending on a high note for stockholders of two rocketing ASX small-cap shares. How high?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/2-asx-small-cap-shares-rocketing-35-to-54-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ARN.AU","BK7067","BK7095","RAD.AU"],"gpt_icon":0},{"id":"2502079767","title":"$8M deal sees Private Lantheus pick up 12.16% of Radiopharm Theranostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2502079767","media":"The Market Herald","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502079767?lang=en_us&edition=fundamental","pubTime":"2025-01-10 07:59","pubTimestamp":1736467140,"startTime":"0","endTime":"0","summary":"Private entity Lantheus, a similarly minded healthcare player, has acquired just over 12% of Radiopharm  through an $8 million placement.“We have been working closely with Lantheus since the initial investment announced in June 2024, and we are delighted with the collaboration that has been taking place between our two companies,” RAD CEO Riccardo Canevari said after the deal was locked.Shares jumped 40% to 3.4cps – an exaggerated effect based on low liquidity for the $52 million-capped company. The placement, priced at 6cps, was at a 150% premium to the last closing price of 2.4cps.Just last month, the company won approval for human safety studies of its Lu-RAD202 product targeting breast and gastric cancer patients. Lu-RAD202 ‘seeks out’ the chemical signals such cancers secrete once established, with any luck, eventually allowing RAD to produce an effective co-treatment for both conditions.The material provided in this article is for information only and should not be treated as inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/8m-deal-sees-private-lantheus-pick-up-12-16-of-radiopharm-theranostics-2025-01-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LNTH","BK4588","RAD.AU","BK4198","BK7067","BK4585"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":45}]}}